Aktuellt
SENASTE
Redeye comments on Bioinvent’s continued execution of its clinical development programs. Four programs are ongoing, and a further CTA is planned for this year. The company is poised to continue to deliver an interesting news flow during the rest of this year.
LÄS MER
